STAR

Strides Pharma Science Limited

Generic and institutional pharmaceutical company with life-sciences services

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

strides.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1045.20
Market cap
9,636 Cr
Stock P/E
15.7
P/B
3.10
Dividend yield
0.4%
ROE (FY26)
17.7%
ROCE (FY26)
17.6%
Operating margin (FY26)
14.9%
Debt / equity (FY26)
0.54
OCF / EBITDA (FY26)
75.9%
OCF / EBITDA (3Y)
84.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Strides makes generic medicines for the US and other regulated markets, and sells branded and over-the-counter (OTC) medicines in Europe, the UK, Africa and other markets.

Company snapshot

45thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-09-30 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 100.0% of revenue

SegmentRevenue shareRevenuePBTAssets
Bio-pharmaceutical business—0 Cr-12 Cr159 Cr
Pharmaceutical business
100.0%
1,201 Cr209 Cr5,831 Cr

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales999 Cr1,038 Cr1,084 Cr1,088 Cr1,201 Cr1,154 Cr1,190 Cr1,120 Cr1,221 Cr1,195 Cr1,323 Cr1,265 Cr
Operating expenses (approx.)846 Cr844 Cr854 Cr871 Cr965 Cr943 Cr973 Cr902 Cr989 Cr959 Cr1,084 Cr1,036 Cr
EBITDA153 Cr194 Cr230 Cr217 Cr236 Cr210 Cr218 Cr218 Cr232 Cr236 Cr240 Cr230 Cr
OPM %15.3%18.7%21.2%20.0%19.6%18.2%18.3%19.5%19.0%19.8%18.1%18.2%
Other income36 Cr9 Cr-14 Cr13 Cr28 Cr6 Cr12 Cr9 Cr27 Cr107 Cr8 Cr5 Cr
Interest79 Cr79 Cr80 Cr80 Cr82 Cr52 Cr50 Cr47 Cr46 Cr43 Cr42 Cr41 Cr
Depreciation60 Cr51 Cr50 Cr49 Cr51 Cr48 Cr49 Cr49 Cr50 Cr51 Cr53 Cr56 Cr
Profit before tax-157 Cr64 Cr30 Cr85 Cr115 Cr114 Cr106 Cr122 Cr153 Cr245 Cr148 Cr200 Cr
Tax %4.7%15.7%64.8%19.8%18.5%20.9%19.5%13.5%14.1%15.2%12.7%17.1%
Net profit-149 Cr54 Cr10 Cr68 Cr94 Cr90 Cr86 Cr106 Cr132 Cr208 Cr129 Cr165 Cr
EPS (₹)₹-14.54₹5.43₹1.98₹7.64₹10.14₹9.56₹8.92₹10.81₹13.84₹21.93₹13.77₹17.02

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,755 Cr2,839 Cr3,012 Cr2,752 Cr3,316 Cr3,070 Cr3,688 Cr4,051 Cr4,565 Cr4,859 CrSign in free for the trailing twelve months
Operating expenses (approx.)2,228 Cr2,443 Cr2,557 Cr2,236 Cr2,681 Cr3,090 Cr3,258 Cr3,308 Cr3,763 Cr3,933 CrSign in free for the trailing twelve months
EBITDA527 Cr397 Cr455 Cr516 Cr635 Cr-20 Cr430 Cr743 Cr803 Cr925 CrSign in free for the trailing twelve months
OPM %19.1%14.0%15.1%18.7%19.1%-0.7%11.7%18.3%17.6%19.0%Sign in free for the trailing twelve months
Other income161 Cr94 Cr45 Cr53 Cr51 Cr132 Cr90 Cr40 Cr59 Cr151 CrSign in free for the trailing twelve months
Interest183 Cr196 Cr205 Cr156 Cr150 Cr177 Cr261 Cr314 Cr249 Cr179 CrSign in free for the trailing twelve months
Depreciation126 Cr154 Cr172 Cr174 Cr206 Cr233 Cr243 Cr221 Cr192 Cr202 CrSign in free for the trailing twelve months
Profit before tax343 Cr706 Cr344 Cr49 Cr289 Cr-653 Cr-268 Cr-63 Cr3,675 Cr669 CrSign in free for the trailing twelve months
Tax %18.5%3.6%4.2%36.9%10.9%27.3%20.7%-50.4%2.1%14.1%Sign in free for the trailing twelve months
Net profit446 Cr680 Cr330 Cr31 Cr258 Cr-474 Cr-212 Cr-94 Cr3,598 Cr575 CrSign in free for the trailing twelve months
EPS (₹)₹44.73₹73.81₹36.25₹4.06₹29.96₹-51.28₹-22.49₹-7.76₹390.54₹60.34Sign in free for the trailing twelve months
Dividend payout %————7.0%———0.6%6.4%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital89 Cr90 Cr90 Cr90 Cr90 Cr90 Cr90 Cr92 Cr92 Cr92 Cr
Reserves2,659 Cr2,365 Cr2,559 Cr2,438 Cr2,687 Cr2,269 Cr2,122 Cr2,034 Cr2,460 Cr3,015 Cr
Borrowings3,032 Cr2,496 Cr3,146 Cr1,833 Cr1,906 Cr2,792 Cr2,774 Cr2,415 Cr1,796 Cr1,669 Cr
Other liabilities2,191 Cr1,439 Cr2,058 Cr1,724 Cr2,295 Cr1,801 Cr1,691 Cr1,354 Cr1,667 Cr2,109 Cr
Total liabilities8,105 Cr6,544 Cr8,006 Cr6,152 Cr7,015 Cr6,976 Cr6,638 Cr5,840 Cr6,049 Cr6,927 Cr
Fixed assets (net)978 Cr665 Cr1,037 Cr1,316 Cr1,272 Cr1,457 Cr1,324 Cr879 Cr881 Cr992 Cr
CWIP205 Cr322 Cr102 Cr148 Cr228 Cr56 Cr48 Cr80 Cr100 Cr161 Cr
Investments1,525 Cr588 Cr779 Cr622 Cr766 Cr554 Cr502 Cr315 Cr420 Cr292 Cr
Loans & advances——54 Cr15 Cr4 Cr5 Cr8 Cr13 Cr10 Cr8 Cr
Inventories733 Cr552 Cr871 Cr783 Cr1,201 Cr1,174 Cr1,147 Cr1,126 Cr1,278 Cr1,635 Cr
Trade receivables996 Cr882 Cr987 Cr932 Cr1,107 Cr1,207 Cr1,299 Cr1,142 Cr1,203 Cr1,289 Cr
Cash & bank322 Cr256 Cr366 Cr182 Cr126 Cr171 Cr304 Cr161 Cr113 Cr189 Cr
Other assets3,347 Cr3,279 Cr3,809 Cr2,154 Cr2,312 Cr2,352 Cr2,006 Cr2,125 Cr2,044 Cr2,361 Cr
Total assets8,105 Cr6,544 Cr8,006 Cr6,152 Cr7,015 Cr6,976 Cr6,638 Cr5,840 Cr6,049 Cr6,927 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity288 Cr187 Cr60 Cr205 Cr481 Cr-258 Cr44 Cr701 Cr684 Cr703 Cr
Cash from investing-687 Cr583 Cr-148 Cr1,306 Cr-521 Cr-119 Cr302 Cr-150 Cr-90 Cr-173 Cr
Cash from financing338 Cr-1,016 Cr194 Cr-1,709 Cr-16 Cr421 Cr-214 Cr-693 Cr-643 Cr-453 Cr
Net cash flow-60 Cr-246 Cr106 Cr-199 Cr-56 Cr45 Cr133 Cr-142 Cr-48 Cr76 Cr
Free cash flow (OCF − Capex)-394 Cr-216 Cr-269 Cr55 Cr184 Cr-401 Cr-51 Cr583 Cr442 Cr280 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %8.9%17.7%9.2%4.6%9.3%-9.2%-0.1%5.6%89.5%17.6%
ROE %13.9%26.1%11.6%1.4%9.5%-19.3%-9.3%-3.4%138.9%17.7%
Debtor days1321131191241221431281039697
Inventory days329237316280314392289307315382
Days payable348306325285309358248232255306
Cash conversion cycle11344111118127177170178156172
OCF / EBITDA %54.6%47.2%13.2%39.7%75.8%—10.3%94.3%85.2%75.9%
OCF / EBITDA % (3 years)——38.8%33.1%46.5%37.9%25.7%42.3%72.4%84.5%
Debt / equity1.101.021.190.730.691.181.281.170.700.54
Current ratio1.221.311.130.931.030.991.051.031.201.25
Net debt / EBITDA5.14—6.113.202.80—5.743.032.101.60